The foldable iPhone arrives September 2022 latest leaks reveal: Apple's plans to develop a foldable iPhone (which, according to rumors, will be called iPhone Flip) are an open secret thanks to the influx of patent applications in recent weeks, as Techradar collects.
However, the latest leak points out that the company has progressed beyond planning and is actively working on this prototype.
Economic Daily News noted last Monday that Apple has sent several prototypes to its manufacturing supplier Foxconn for testing.
Thus, this information explains that the company aims to make its folding device capable of supporting at least 100,000 folds and is weighing whether to use an OLED or micro-LED display.
Rumors point out that Apple will try to launch its new phone in September 2022 coinciding with what would be the iPhone 14, although it is not clear if it would be the same terminal or a separate model.
The foldable iPhone arrives September 2022 latest leaks reveal
A leak occurred last week suggests that this foldable iPhone would arrive in 2022, replace the iPad Mini in the Apple line, it would sell for 1.499 dollars, it would have 256 GB of storage and 8GB of RAM. However, the informant in question does not have a large success rate in his predictions, so it is necessary to take this information carefully.
Apple has taught several patents on its possible folding phone over the past two years. The first came out in 2019 and showed an iPhone with a single screen that folds on itself, being Z-shaped when closed.
This model seems rather unlikely, since, according to a leak at the beginning of the year, the iPhone Flip could be made from the separate screens connected by a hinge.
The foldable iPhone arrives September 2022 latest leaks reveal
Your new home office - Take working from home to the next level with our range of fully insulated garden office products and enjoy 10 years guarantee: GARDEN OFFICES
What Pfizer and modern coronavirus vaccine results say (and don't)
In recent weeks, two companies have announced that their coronavirus vaccines, which are in the last phase of clinical trials, have shown more than 90% effectiveness in preventing infections.
The news has been enthusiastically received by markets, industry and experts, who, although cautious, celebrate the results and assure that they are promising.
The companies have announced the results through a press release and have not yet been published in any scientific journal, so we must be cautious when drawing conclusions.
In addition, it should be borne in mind that the findings correspond to a short period of time and do not allow to anticipate how the vaccine works in the long term.
"We have to be cautious because these results, being good and hopeful, are very preliminary and the data have not been made public. Pfizer's announcement comments that the vaccine has a 90% efficacy at 7 days after the second vaccine dose. Seven days is a very short period of time to estimate the effectiveness of a vaccine. We hope that this effectiveness will be maintained for weeks and months, " explains Dr. María Montoya, researcher at the Center for Biological Research Margarita Salas of the CSIC (CIB-CSIC) and member of the board of Directors of the Spanish Society of Immunology, to Business Insider Spain.
Here's what we know (and what we don't) about vaccines and the role they can play in fighting the pandemic.
The effectiveness of long-term vaccines is not guaranteed
A common challenge for all vaccines that come to market is that it will not be known for how long they guarantee protection.
"We do not know at this time what the duration of protection will be," recently assured Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, as stated by STAT.
Isabel Sola, senior scientist and co-director along with Luis Rincanes of the coronavirus Laboratory of the National Biotechnology Center (CNB) of the Superior Council of Scientific Research (CSIC), assured in a previous interview with Business Insider Spain that vaccines that have completed the trials can be put on the market with the peace of mind that they are "safe and effective"vaccines.
"We will not know how long the immunity lasts, because it will not have given time to follow the volunteers for a long time," she acknowledged even so alone, " but it will be the only question. Otherwise, they will be safe and induce immunity."
For Dr. Montoya, the success of Pfizer and modern vaccines should not the development of other vaccines. "It's hopeful, but more vaccines need to be developed. First, because we do not know the duration of each vaccine and, secondly, because we do not know its long-term effectiveness," he notes.
On the other hand, the design of the trials of both vaccines has some limitations that makes it difficult to know what their actual effectiveness is in some cases. Neither modern nor Pfizer evaluate whether the vaccine prevents infections and symptomatic diseases, which are the key to controlling the spread of the virus.
"The data we have is that these vaccines protect you against serious diseases, but it doesn't mean you can't get infected and pass it on to your patient, your neighbor, your client or whoever," warns Ruth Karron, who heads the Immunization Research Center at Johns Hopkins University's Bloomberg School of Public Health, to Science.
The data of the companies, which have been more detailed in the case of Moderna, reveal that the vaccine has some adverse effect, but none of particular severity.
Some of the symptoms observed in the case of Pfizer were fever and pain; while the modern candidate seems to cause more fatigue and headache.
But the most important safety data will not arrive until patients have been followed for months and even years. Pfizer and Moderna have promised to collect and disclose that information in time, says STAT.
Despite the safety of clinical trials, vaccines are expected to cause some unobserved effects until they begin to be administered massively.
"These are vaccines that have side effects, it is an unknown," Gary Nabel, scientific director of the pharmaceutical company Sanofi, which is currently working on two candidates for the COVID-19 vaccine, tells The Financial Times. "No matter how big a trial of 30,000 people is, when you go out into the world of millions of people, things will happen."
In fact, the UK wants to anticipate the phenomenon and would be exploring the possibility of using artificial intelligence to track the potential side effects that coronavirus vaccines may cause in the population once they reach the market
The relevant health regulatory agency in the UK assures that, based on previous vaccination campaigns, between 50,000 and 100,000 reports of possible side effects per 100 million doses could be expected over a period of 6 to 12 months.
However, it ensures that all vaccines, including coronavirus, are subjected to rigorous testing and that most reactions will be mild and short-term.
Pfizer and Moderna's announcements have undoubtedly been held in the offices of other pharmacists in the race for the coronavirus vaccine despite competition to achieve a market that could be worth millions a year for the winner.
On the one hand, both vaccines use messenger RNA, a pioneering technique that has never before achieved approval for human use. "In the event that the results are sufficient for the drug agencies of each country to approve it, it would be the first vaccine with an mRNA construction, so it would open the doors to other vaccines based on this concept," explains Dr. Montoya.
The companies ' results validate the mRNA platform, which is being used by many other pharmacists who are developing a coronavirus vaccine.
On the other hand, both vaccines target the protein s, a spicule on the surface of the virus that is vital for it to penetrate the cell. The vast majority of major vaccines in development have opted for this strategy, so Pfizer and Moderna's findings allow a sigh of relief to the entire industry and increase the chances of more effective vaccines arriving.
"We believe that these interim results also increase the likelihood of success of other candidate vaccines against COVID-19 that use a similar approach," assures CEPI CEO Richard Hatchett in a statement collected by STAT.
"In a vaccine there are two components, a vaccine vehicle and the protein or antigen that comes from the pathogen, in this case SARS-CoV-2. These results are hopeful for vaccines that use SARS-CoV-2 S, even with another vaccine vehicle," confirms Dr. Montoya.
Finally, the big question around these vaccines is whether they will really make a big difference when it comes to curbing the pandemic.
For now, the answer is that in the short term probably not. Doses will be very limited due to manufacturing and distribution challenges and will be administered first to the highest risk and most exposed collectives.
However, especially as manufacturers scale up their production capacity and as more vaccines come to market, people may gain more immunity that, while not removing all other restrictions altogether, will ensure a certain level of protection.
The Minister of Health, Salvador Illa, has recently assured that he is confident that there will be a sufficient number of Spanish population vaccinated against coronavirus by the month of May.